

# Stanford

---



## Nikolaus Jahn

Postdoctoral Scholar, Pathology

### Bio

---

#### STANFORD ADVISORS

- Sidd Jaiswal, Postdoctoral Faculty Sponsor

### Research & Scholarship

---

#### LAB AFFILIATIONS

- Sidd Jaiswal (10/1/2020)

### Publications

---

#### PUBLICATIONS

- **Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.** *Leukemia*  
Jahn, E., Saadati, M., Fenaux, P., Gobbi, M., Roboz, G. J., Bullinger, L., Lutsik, P., Riedel, A., Plass, C., Jahn, N., Walter, C., Holzmann, K., Hao, et al  
2023
- **Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.** *Nature*  
Weinstock, J. S., Gopakumar, J., Burugula, B. B., Uddin, M. M., Jahn, N., Belk, J. A., Bouzid, H., Daniel, B., Miao, Z., Ly, N., Mack, T. M., Luna, S. E., Prothro, et al  
2023
- **Clonal Hematopoiesis and Its Impact on Human Health.** *Annual review of medicine*  
Ahmad, H., Jahn, N., Jaiswal, S.  
2022
- **Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.** *Leukemia*  
Jahn, N., Jahn, E., Saadati, M., Bullinger, L., Larson, R. A., Ottone, T., Amadori, S., Prior, T. W., Brandwein, J. M., Appelbaum, F. R., Medeiros, B. C., Tallman, M. S., Ehninger, et al  
2022
- **Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.** *Blood*  
Schmalbrock, L. K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T. J., Herzig, J. K., Skambraks, S., Rücker, F. G., Gaidzik, V. I., Paschka, et al  
2021
- **Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.** *Blood advances*  
Jahn, N., Terzer, T., Sträng, E., Dolnik, A., Cocciardi, S., Panina, E., Corbacioglu, A., Herzig, J., Weber, D., Schrade, A., Götze, K., Schröder, T., Lübbert, et al  
2020; 4 (24): 6342-6352
- **Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial.** *Blood*  
Kapp-Schwoerer, S., Weber, D., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Krönke, J., Theis, F., Rücker, F. G., Teleanu, M. V., Panina, E., Jahn, N., Herzig, J. K., Kubanek, et al

---

2020

- **Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22; q22.1) acute myeloid leukemia (AML) LEUKEMIA**

Agrawal, M., Schwarz, P., Giaimo, B., Bedzhov, I., Corbacioglu, A., Weber, D., Gaidzik, V. I., Jahn, N., Ruecker, F. G., Schroeder, T., Kindler, T., Wattad, M., Goetze, et al  
2020; 34 (2): 630–34

- **Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1) LEUKEMIA**

Meyer, T., Jahn, N., Lindner, S., Roehner, L., Dolnik, A., Weber, D., Scheffold, A., Koepff, S., Paschka, P., Gaidzik, V. I., Heckl, D., Wiese, S., Ebert, et al  
2020; 34 (2): 404–15

- **Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group BLOOD**

Ruecker, F. G., Agrawal, M., Corbacioglu, A., Weber, D., Kapp-Schwoerer, S., Gaidzik, V. I., Jahn, N., Schroeder, T., Wattad, M., Luebbert, M., Koller, E., Kindler, T., Goetze, et al  
2019; 134 (19): 1608–18

- **Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood**

Döhner, K. n., Thiede, C. n., Jahn, N. n., Panina, E. n., Gambietz, A. n., Larson, R. A., Prior, T. W., Marcucci, G. n., Jones, D. n., Krauter, J. n., Heuser, M. n., Voso, M. T., Ottone, et al  
2019

- **Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group LEUKEMIA**

Jahn, N., Agrawal, M., Bullinger, L., Weber, D., Corbacioglu, A., Gaidzik, V. I., Schmalbrock, L., Thol, F., Heuser, M., Krauter, J., Goehring, G., Kuendgen, A., Fiedler, et al  
2017; 31 (4): 1012–15

- **Intermediate Monocytes but Not TIE2-Expressing Monocytes Are a Sensitive Diagnostic Indicator for Colorectal Cancer PLOS ONE**

Schauer, D., Starlinger, P., Reiter, C., Jahn, N., Zajc, P., Buchberger, E., Bachleitner-Hofmann, T., Bergmann, M., Stift, A., Gruenberger, T., Brostjan, C.  
2012; 7 (9): e44450